Vivera Pharmaceuticals, a vertically integrated company, announced their TABMELT technology had been granted a patent from the Israel Patent Office on Jan. 5, according to a press release.
TABMELT is a sublingual drug delivery system that allows patients to take medicine by dissolving a tablet under the tongue.
Vivera has numerous divisions, including its technologies, biosciences, medical devices and advanced diagnostics divisions.
"TABMELT has already received international patent grants in Canada, Russia, Australia and the United Kingdom," Paul Edalat said, chairman, founder and CEO of Vivera.
The Israel patent is to support patients by having a more efficient delivery system and top-of-the-line research capability.
"This long-awaited Israel patent is going to allow us to give more patients access to this innovative drug delivery system," Edalat said. "From advancements in research and development and state-of-the-art manufacturing capabilities, Israel is a major player in the pharmaceutical industry, and the partnership opportunities are truly endless."
According to the release, the company holds global exclusivity to TABMELT. It maintains its own issued patents on ZICOH, a smart dose-controlled electronic medical device, and MDZone, a portable telemedicine station.